OKYO Pharma director reports initial holdings
OKYO Pharma Ltd director Simon Willy Jules has filed a Form 3 reporting his initial ownership in the company.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
OKYO Pharma Ltd director Simon Willy Jules has filed a Form 3 reporting his initial ownership in the company. He holds 6,435 shares of common stock directly and 8,948 shares indirectly through his spouse. He also reports multiple option awards over common stock, including grants covering 12,500 shares at an exercise price of $1.50 per share and 5,000 shares at $1.65 per share, with expiration dates running from 2033 to 2035. These positions show his existing equity and option exposure rather than new market transactions.
Insider Trade Summary
Holdings reported, no transactions
Holdings
Insider
Simon Willy Jules
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | Options | -- | -- | -- |
| Holding | COMMON STOCK | -- | -- | -- |
| Holding | COMMON STOCK | -- | -- | -- |
Holdings:
Options — 129,002 contracts (Direct);
COMMON STOCK — 6,435 shares (Direct);
COMMON STOCK — 8,948 shares (Indirect, Holding of spouse)
Key Figures
Direct common shares: 6,435 shares
Indirect common shares (spouse): 8,948 shares
Option block at $1.50: 12,500 underlying shares
+3 more
6 metrics
Direct common shares
6,435 shares
Total common stock held directly following reported holdings
Indirect common shares (spouse)
8,948 shares
Common stock held indirectly as holding of spouse
Option block at $1.50
12,500 underlying shares
Options over common stock at $1.50, expiring 2035-03-25
Option block at $1.46
13,334 underlying shares
Options over common stock at $1.46, expiring 2034-03-13
Option block at $1.65
5,000 underlying shares
Options over common stock at $1.65, expiring 2033-11-24
Option block at $2.13
1,540 underlying shares
Options over common stock at $2.13, expiring 2033-03-14
Key Terms
Form 3, indirect ownership, exercise price, expiration date, +1 more
5 terms
Form 3 regulatory
"Simon Willy Jules has filed a Form 3 reporting his initial ownership."
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
indirect ownership financial
"He reports 8,948 shares of common stock as indirect ownership through his spouse."
exercise price financial
"Option awards include grants at an exercise price of $1.50, $1.46, $1.65 and $2.13 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"The options have an expiration date range from 2033 to 2035."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying common stock financial
"Each option grant references underlying common stock with specified share amounts."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Simon Willy Jules report in his OKYO Pharma (OKYO) Form 3 filing?
Simon Willy Jules reports his initial ownership in OKYO Pharma, including direct and indirect common stock plus several option awards. The filing outlines his equity exposure as a director, without indicating any recent purchases or sales.
What stock options for OKYO Pharma does Simon Willy Jules report holding?
He reports multiple option grants over OKYO Pharma common stock, including blocks of 12,500 shares at $1.50, 13,334 and 13,333 shares at $1.46, and 5,000 shares at $1.65. Additional smaller grants are listed at an exercise price of $2.13.
When do the OKYO Pharma stock options held by Simon Willy Jules expire?
The options disclosed in the Form 3 have expiration dates ranging from 2033-03-14 to 2035-03-25. These long-dated expirations indicate multi‑year potential for conversion into common stock if exercised.
Are there any buy or sell transactions in Simon Willy Jules’s OKYO Pharma Form 3?
The Form 3 records holdings rather than transactions, with transaction codes listed as unknown and no buy or sell amounts. It functions as an initial statement of beneficial ownership instead of reporting new market trades.
AI-generated analysis. How Rhea-AI works. Not financial advice.
